Stanislaw Rajmund Burzynski, Stanislaw R. Burzynski, Stanislaw Burzynski, Stan R. Burzynski, Stan Burzynski, S. R. BURZYNSKI, S. Burzynski, Arthur Burzynski, Hippocrates Hypocrite Hypocrites Critic Critics Critical HipoCritical
Tag Archives: http://www.ncbi.nlm.nih.gov/m/pubmed/
Liz Szabo’sUSA TODAY “killer cancer” article as interpreted by “Orac” made 3 claims [0]:
—————————————————————— “Conventional cancer treatment can also cause tumors to swell temporarily,”[1]
“due to”
“inflammation,” [2]
“A patient who isn’t familiar with this”
“phenomenon” [3]
“may assume her tumor is growing”
——————————————————————
The issue with citing these 3 studies is that each then needs to be reviewed to determine if they have any relevance to the patientsBurzynski has treated in the phase II clinical trials:
—————————————————————— [1] – 12/2009 – Pseudoprogression and pseudoresponse in the treatment of gliomas
—————————————————————— 1. Has Burzynskitreated patients with gliomas, brain tumours, or recurrent glioblastoma ?
—————————————————————— 2. Has Burzynski’spatients been treated with combined chemo-irradiation with temozolomide which may induce in 20-30% ?
—————————————————————— [2] – 5/2008 – Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
—————————————————————— 1. Has Burzynskitreated patients with glioblastoma ?
—————————————————————— 2. Have any of Burzynski’spatients been treated with temozolomide chemoradiotherapy ?
—————————————————————— 3. so-called pseudoprogression can occur in up to 20% of patients
—————————————————————— 4. can explain about 1/2 of 20%
—————————————————————— [3] – In support of this “phenomenon”, the article provides a link to a Canadian web-site which posits:
—————————————————————— “RT/TMZ is now widely practiced and the standard of care for appropriately selected patients, we are learning more about the consequences of RT/TMZ”
“One phenomena, termed Pseudo-Progression (psPD)…”
——————————————————————
The problem is that this only applies to “Glioblastoma Multiforme (GBM)”, and the article provides NO proof whatsoever, that any of Burzynski’s “Glioblastoma Multiforme (GBM)” patients have taken “RT/TMZ”
——————————————————————
Additionally, the sitecites the reference as:
Sanghera, Perry, Sahgal, et al., “Sunnybrook Health Sciences Odette Cancer Centre” (in press, Canadian Journal of Neuroscience)
(“In press” refers to journal articles which have been accepted for publication, but have not yet been published)
However, the journal article in question was published 1/2010, so it has NOT been “in press” for over 3 years and 7 months [4]
—————————————————————— GorskGeek stupidly suppositories:
—————————————————————— “It’s very heartening to see a story like this in a major news outlet, and I must congratulate Ms. Szabo for her thorough deconstruction of the phenomenon that is Stanislaw Burzynski“
—————————————————————— GorskGeek, just because a great portion of Liz Szabo’sUSA TODAYarticlequoted verbatim from The Skeptics™ play book, does NOT mean she was anymore successful at “deconstructing” Burzynski [5], anymore than you have NOT
—————————————————————— GorskGeek then regurgitates:
—————————————————————— “Remember how I said that Bob Blaskiewicz will want your help?”
The above chart is used for ease of reading since it is similar to the one used by Gorski in his article. The below relates to Gorski’s chart
Data as of July 17, 2011 based on medical records of the first 1770 evaluable patients
—————————————————————— The table shows response rates for 22 selected common cancer types treated at the Burzynski Clinic (by highest rate of OR – Objective Response)
—————————————————————— DEFINITIONS:
—————————————————————— OR – Objective Response includes CR, PR, MR & IM
—————————————————————— CR – Complete Response. Complete disappearance of all signs of cancer in response to treatment of 4 weeks or longer
—————————————————————— PR – Partial Response. More than 50% decrease in the size of the tumors (the sum of cross-sectioned area of the tumor) in response to treatment of 4 weeks or longer
—————————————————————— MR – Minor Response. Significant decrease (more than 25% in the size of tumors with simultaneous increase in size of some of the other tumors
—————————————————————— IM – Improvement. Decrease in size of the tumors, not confirmed yet by the second follow-up radiological measurement
—————————————————————— SD – Stable Disease
—————————————————————— PD – Progressive Disease
====================================== [1] – 12/12/2012 – Gorski posted: Stanislaw Burzynski: A pioneering cancer researcher or a quack?
“What I found interesting is a table that posted from the brochure”
“Looking at the table, I noticed immediately that Dr. Burzynski says nothing about survival rates, only “objective response rates,” which are not defined in a meaningful way”
—————————————————————— Gorski, what do you NOT understand about:
Objective Response (OR) includes:
Complete Response (CR) Partial Response (PR) Minor Response (MR) Improvement (IM)
—————————————————————— [1] – 12/12/2012 – “The pamphlet defines them as as anything from an “improvement” (defined as “decrease in size of the tumors, not confirmed yet by the second follow-up radiological measurement”) to “complete disappearance of all signs of cancer,” which is utter bollocks”
“There are standardized ways of measuring tumor response agreed upon by radiologists and oncologists, such as the RECIST criteria”
“Burzynski lumps all responses together in an oncologically meaningless way”
—————————————————————— Gorski, when I did a search in PubMed on this data, why did I get these results ?
National Cancer Institute (NCI) defines Complete Response (CR) as the “disappearance of all signs of cancer in response to treatment.”
—————————————————————— [36] – 12/1998 – “Partial Response” (PR) Response Evaluation Criteria in Solid Tumors (RECIST) Quick Reference:
At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD
—————————————————————— [37] – 1/20/2006 – “Minor Response” (MR) FDA/AACR/ASCO
Public Workshop on Brain Tumor Clinical Trial Endpoints
—————————————————————— [38] – 5/2007 – “Stable Disease” (SD) Response Evaluation Criteria in Solid Tumors (RECIST) Quick Reference:
Neither sufficient shrinkage to qualify for Partial Response (PR) nor sufficient increase to qualify for Progressive Disease (PD), taking as reference the smallest sum LD since the treatment started
—————————————————————— [39] – 4/2008 – “Progressive Disease” (PD) Response Evaluation Criteria in Solid Tumors (RECIST) Quick Reference:
